References

1. CFR Regulations, Title 21, Parts 300-314. CFR, 1998.

2. Galluppi, G.R., M.C. Rogge, L.K. Roskos, L.J. Lesko, M.D. Green, D.W. Feigal, Jr., and C.C. Peck, Integration of pharmacokinetic and pharmacodynamic studies in the discovery, development, and review of protein therapeutic agents: a conference report. Clin Pharmacol Ther, 2001. 69(6): 387-99.

3. FDA, T., FDA final rule, October 15,1996, published through REGO (under the President's reinventing government) initiative. 1996.

4. "Drug discovery: filtering out failures early in the games,". Chem Eng News, 2000.78: 63.

5. Borchardt, R.T., Integrating drug discovery and development. AAPS Newsmagazine, 2001. 4(5): 5.

6. Navia, M.A., P.M. Fitzgerald, B.M. McKeever, C.T. Leu, J.C. Heimbach, W.K.

Herber, I.S. Sigal, P.L. Darke, and J.P. Springer, Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature, 1989.337(6208): 615-20.

7. Vacca, J.P., Design of tight-binding human immunodeficiency virus type 1 protease inhibitors. Methods Enzymol, 1994. 241: 311-34.

8. Vacca, J.P., B.D. Dorsey, W.A. Schleif, R.B. Levin, S.L. McDaniel, P.L. Darke, J. Zugay,

J.C. Quintero, O.M. Blahy, E. Roth, and et al., L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci USA, 1994. 91(9): 4096-100.

9. Elimination of ELA and PLA requirement, May 14,1996 and replaced by BLA. Federal Register, 1996. 63(147): 40858-71.

10. Devine, R., Manufacture process modification, effective Oct 7, 1997; CBER,. CBER, presentation, 1997.

0 0

Post a comment